APVO

Aptevo Therapeutics Inc

1.09

Nov 10 • 2:28 PM ET -0.04 (-3.68%)

Healthcare Biotechnology USA Nano NASD

Nov 09, 9:10 AMAptevo Therapeutics reports SITC 2026 preclinical data showing multispecifics APVO451, APVO452 and APVO711 drive immune tumor-cell killing in immunosuppressive solid tumors

Peers: GTBP HCWB XLO HOWL MGNX JANX ATNM CUE CTMX TCRT

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	1.97M
Enterprise Value	-3.62M
Income	-28.08M
Sales	0.00M
Book/sh	4.26
Cash/sh	5.40
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	36
IPO	Jul 20, 2016

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.26
P/C	0.20
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	2.08
Current Ratio	2.08
Debt/Eq	0.70
LT Debt/Eq	0.54
Option/Short	No / Yes

EPS (ttm)	-57.76
EPS next Y	-6.59
EPS next Q	-3.71
EPS this Y	80.47%
EPS next Y	61.33%
EPS next 5Y	58.56%
EPS past 3/5Y	- 89.05%
Sales past 3/5Y	- -
EPS Y/Y TTM	99.41%
Sales Y/Y TTM	-
EPS Q/Q	96.49%
Sales Q/Q	-
Earnings	Aug 14 BMO
EPS/Sales Surpr.	11.72% -

Insider Own	5.81%
Insider Trans	0.00%
Inst Own	3.29%
Inst Trans	2.61%
ROA	-185.67%
ROE	-445.43%
ROIC	-299.90%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-24.08%
SMA50	-35.46%
SMA200	-73.39%
Trades

Shs Outstand	1.81M
Shs Float	1.70M
Short Float	5.68%
Short Ratio	0.97
Short Interest	0.10M
52W High	28.08 -96.12%
52W Low	1.07 1.72%
Volatility	13.09% 9.00%
ATR (14)	0.13
RSI (14)	19.56
Beta	1.63
Rel Volume	0.47
Avg Volume	99.14K
Volume	36,227

Perf Week	-19.97%
Perf Month	-40.73%
Perf Quarter	-68.90%
Perf Half Y	-77.47%
Perf YTD	-88.46%
Perf Year	-96.12%
Perf 3Y	-100.00%
Perf 5Y	-100.00%
Perf 10Y	-100.00%
Recom	1.00
Target Price	25.50
Prev Close	1.13
Price	1.09
Change %	-3.68%

Consensus

Strong Buy

Avg. Price Target

$25.50

Implied Upside

+2,242.9%

Analysts2incl. previous ratings

Rating Distribution2 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Nov 05, 2018	Initiated	LLadenburg Thalmann	Buy
Oct 05, 2017	Resumed	PPiper Jaffray	Overweight	$6	+451.3%

Nov-09-26 08:30AM	Aptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors (ACCESSWIRE) -8.87%
Nov-05-26 08:30AM	Aptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Frontline AML (ACCESSWIRE) -7.30%
Oct-26-26 08:05AM	Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant (ACCESSWIRE) -6.83%
Oct-14-26 08:46AM	Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting (ACCESSWIRE)
Sep-24-26 08:05AM	Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development (ACCESSWIRE)
10:19AM	Loading…
Sep-03-26 10:19AM	Aptevo Reports 93% Clinical Benefit Rate for Mipletamig Triplet in TP53-Mutated AML (InvestorsHub) -34.23%
08:05AM	Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML (ACCESSWIRE)
Aug-14-26 08:05AM	Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results (ACCESSWIRE) -13.53%
Aug-13-26 04:05PM	Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds (ACCESSWIRE)
Aug-12-26 09:30AM	Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds (ACCESSWIRE) -15.38%
Jul-27-26 08:05AM	Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone (ACCESSWIRE)
Jun-30-26 08:05AM	Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors (ACCESSWIRE)
May-28-26 08:05AM	Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer (ACCESSWIRE)
May-27-26 08:05AM	Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing (ACCESSWIRE)
May-13-26 08:05AM	Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection (ACCESSWIRE)
08:05AM	Loading…
May-06-26 08:05AM	Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection (ACCESSWIRE) -7.66%
Mar-26-26 08:05AM	Aptevo Provides State of the Business Report and 2025 Financial Results (ACCESSWIRE)
Mar-19-26 08:05AM	Aptevo to Participate in March 2026 Conferences (ACCESSWIRE)
Mar-10-26 08:05AM	Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50% (ACCESSWIRE) -22.79%
Feb-03-26 08:05AM	Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth (ACCESSWIRE) -10.34%
Jan-09-26 08:05AM	Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality (ACCESSWIRE) +5.00%
Dec-26-25 08:05AM	Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split (ACCESSWIRE) -34.73%
Dec-09-25 08:05AM	Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025 (ACCESSWIRE) -7.46%
Nov-19-25 09:55AM	Aptevo Therapeutics (APVO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks) -7.58%
Nov-10-25 08:05AM	Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors (ACCESSWIRE) +6.12%
Nov-06-25 08:05AM	Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update (ACCESSWIRE)
Oct-08-25 08:20AM	Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter (ACCESSWIRE)
Sep-16-25 08:30AM	Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML (ACCESSWIRE)
Sep-04-25 08:45AM	Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules (ACCESSWIRE)
Aug-13-25 08:05AM	Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer (ACCESSWIRE) -7.28%
08:05AM	Loading…
Aug-11-25 08:05AM	Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update (ACCESSWIRE)
Jul-15-25 04:57PM	Aptevo Meets Nasdaq $2.5M Equity Requirement (Insider Monkey)
Jun-21-25 09:00AM	Aptevo announces addition of preclinical candidate APVO455 to portfolio (TipRanks)
Jun-20-25 11:30AM	Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) -18.71%
08:55AM	Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers (ACCESSWIRE)
Jun-18-25 10:52AM	Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) +81.91%
08:01AM	Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML (ACCESSWIRE)
Jun-13-25 08:05AM	Aptevo Participating in the BIO International Convention (ACCESSWIRE) -8.16%
May-22-25 08:05AM	Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan (ACCESSWIRE) -21.05%
May-15-25 08:05AM	Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig (ACCESSWIRE)
May-08-25 08:45AM	Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation (ACCESSWIRE) -7.69%
Apr-22-25 04:05PM	Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) +9.08% +6.72%
Apr-21-25 02:40PM	Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -26.24%
Apr-04-25 04:05PM	Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -25.13% -6.71%
Apr-03-25 08:50AM	Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) +44.20%
Mar-20-25 02:26PM	Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment (Benzinga) -6.09%
08:35AM	RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment (ACCESSWIRE)
Mar-18-25 08:05AM	Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy (ACCESSWIRE)
Mar-06-25 08:00AM	Aptevo to Participate in March Conferences (ACCESSWIRE)
Feb-15-25 06:59PM	Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESS Newswire)
Feb-14-25 08:05AM	Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update (ACCESSWIRE) -8.24%
Jan-15-25 08:00AM	Aptevo's Peter Pavlik, PhD, Chairing Session on 'Bi and Multispecific Biologics' at Cambridge Healthcare Institute's Pep Talk 2025 (ACCESSWIRE)
Dec-12-24 12:50PM	Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds (ACCESSWIRE) -43.76%
09:00AM	100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial (ACCESSWIRE)
Dec-04-24 08:35AM	Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects (ACCESSWIRE) +15.01%
Nov-29-24 09:55AM	Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan (ACCESSWIRE) -18.88%
Nov-26-24 08:35AM	Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation (ACCESSWIRE) +9.20%
Nov-22-24 08:35AM	Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm (ACCESSWIRE) +15.33%
Nov-20-24 08:35AM	First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies (ACCESSWIRE) +16.05%
Nov-11-24 08:15AM	First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial (ACCESSWIRE)
Nov-07-24 08:05AM	Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update (ACCESSWIRE) +19.77%
Oct-29-24 08:05AM	Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024 (ACCESSWIRE) +27.95%
Sep-18-24 04:05PM	Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) -19.55% +6.93%
Sep-16-24 08:05PM	Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) -7.02% -38.00%
08:20AM	Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study (ACCESSWIRE)
08:05AM	Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study (ACCESSWIRE)
Sep-13-24 08:20AM	Alligator Bioscience and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types at ESMO Congress 2024 (ACCESSWIRE)
08:05AM	Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024 (ACCESSWIRE)
Aug-13-24 08:05AM	Phase 1b/2 'RAINIER' Frontline Acute Myeloid Leukemia (AML) Trial Initiated (ACCESSWIRE) -8.57%
Aug-08-24 08:05AM	Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update (ACCESSWIRE)
Jul-01-24 04:20PM	Aptevo Therapeutics Announces Closing of $2.75 Million Offering (ACCESSWIRE) +9.15% -10.78%
Jun-28-24 09:20AM	Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) -40.57%
Jun-17-24 07:40AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -20.53%
Jun-03-24 08:05AM	Aptevo Participating in the BIO International Convention (ACCESSWIRE) +10.58%
May-14-24 08:05AM	Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA (ACCESSWIRE)
May-08-24 12:54PM	APVO Stock Earnings: Aptevo Therapeutics Beats EPS for Q1 2024 (InvestorPlace) -11.64%
08:05AM	Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update (ACCESSWIRE)
May-02-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) +17.71%
Apr-16-24 12:47PM	Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why (Zacks)
Apr-15-24 04:05PM	Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering (ACCESSWIRE) -7.35%
Apr-11-24 08:15AM	Why Is Aptevo Therapeutics (APVO) Stock Down 56% Today? (InvestorPlace) -60.08%
08:00AM	Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering (ACCESSWIRE)
Apr-10-24 09:00AM	Aptevo Therapeutics Provides Pipeline Update (ACCESSWIRE) -26.38%
Mar-18-24 06:00AM	Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference (ACCESSWIRE) -8.12%
Mar-07-24 08:55AM	Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4 (ACCESSWIRE)
Mar-05-24 01:51PM	APVO Stock Earnings: Aptevo Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -8.55%
08:05AM	Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update (ACCESSWIRE)
Mar-04-24 09:00AM	Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan (ACCESSWIRE) -13.72%
Nov-14-23 08:05AM	Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update (ACCESSWIRE) +6.82%
Nov-01-23 07:45AM	Aptevo to Present at Bio-Europe Conference (ACCESSWIRE)
Aug-10-23 08:05AM	Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update (ACCESSWIRE) -9.68%
Aug-06-23 07:14AM	10 Oversold Value Stocks To Buy (Insider Monkey)
Aug-04-23 06:40PM	Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering (ACCESSWIRE) -10.19%
Aug-01-23 10:15PM	Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering (ACCESSWIRE) -5.77% -38.30%
Jul-30-23 02:17PM	7 Millionaire-Maker Penny Stocks to Buy Before the Window Closes (InvestorPlace)
Jul-18-23 08:05AM	Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AML (ACCESSWIRE) -23.24%
May-11-23 08:05AM	Aptevo Therapeutics Reports 1Q23 Financial Results and Provides Business Update (ACCESSWIRE)
Apr-01-23 08:51AM	Aptevo Therapeutics Full Year 2022 Earnings: EPS Beats Expectations (Simply Wall St.)
Mar-30-23 07:45AM	Aptevo Therapeutics Reports 2022 Financial Results and Provides Business Update (ACCESSWIRE)
07:30AM	Aptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding (ACCESSWIRE)

Show Previous News

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527, and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA.

Executive ChairMr. Marvin L. White

CEOMr. Jeffrey G. Lamothe CA

LL.M.Ms. SoYoung Kwon J.D.

Senior VP & CFOMs. Daphne L. Taylor CPA

Senior VP & Chief Scientific OfficerMs. Mary J. Janatpour Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

APVO

Aptevo Therapeutics Inc

Upgrade your Finviz experience